Gene profiling in early stage disease.
Although we have made steady progress in the adjuvant chemotherapy of colorectal cancer, it is clear that any population benefits accrued stem from overtreatment of the majority of patients. For example, we have to treat 100 stage II patients to cure 3 or 4, while accepting that up to 40% of those t...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2010
|